Roche’s New Weight-Loss Weapon

AI-generated illustration: RNA drugs are designed to enter fat cells directly and suppress production of the ALK7 receptor there.

Roche Licenses RNAi Obesity Drug from Rona Therapeutics – A Sixth Arrow in the Quiver

Roche has secured the rights to an experimental RNA interference (RNAi) drug — a technology that selectively suppresses the production of a specific protein at the messenger RNA level — targeting obesity. The licensor is Rona Therapeutics, a Chinese biotech company based in Shanghai. I took a closer look at what’s behind the deal, and why it’s typical of a trend that’s fundamentally reshaping the pharmaceutical industry.

What Roche is actually licensing

The drug candidate targets ALK7 (encoded by the ACVR1C gene), a receptor from the TGF-beta growth factor family found primarily in fat cells. ALK7 regulates fat storage, lipolysis, and energy balance in adipose tissue. Human genetic studies show an association between reduced ALK7 activity and a more favorable fat distribution and better metabolic markers — though such associations alone don’t prove a drug’s efficacy or safety.

The appeal lies in the mechanism itself. While today’s dominant weight-loss injections (GLP-1 agonists like semaglutide or tirzepatide) act on appetite and satiety in the brain, this RNAi candidate is designed to work directly in adipose tissue by suppressing ALK7 production. Rona brings its own “extrahepatic” RNAi platform to the table — a technology meant to deliver RNA drugs to target tissues outside the liver. No clinical or robust preclinical data on this specific candidate have been published so far; its development stage has not been publicly confirmed.

Roche receives exclusive worldwide rights. The deal structure: up to $100 million in upfront and near-term milestone payments, plus up to $1.06 billion in additional development, regulatory, and commercial milestones — totaling up to $1.16 billion — plus tiered royalties on future sales, the rates of which were not disclosed. Most of the deal’s value is therefore contingent on milestones still to be achieved.

Why targeting fat tissue with RNAi is so difficult

What the deal announcement doesn’t mention: delivering RNA drugs outside the liver is considered one of the toughest technical challenges in the field. After uptake into a cell, RNA initially lands in endosomes (membrane-bound transport vesicles) and is largely degraded there — estimates suggest less than two percent of RNA ever escapes this trap to reach its target inside the cell. Intravenously administered particles are also preferentially taken up by the liver, thanks to its permeable capillaries, so RNA drugs tend to end up there by default. The liver is therefore considered a largely solved problem (via so-called GalNAc conjugates, where RNA is coupled directly to a sugar molecule that liver cells readily absorb), while tissues like the brain — or, in this case, specific fat tissue — remain frontier territory where no RNAi technology has yet proven itself at scale in the clinic. This is exactly where Rona’s platform aims to make a difference; whether it actually solves the technical problem can only be judged by clinical data, not by the licensing agreement itself.

One deal among many: the China licensing trend

The Rona deal fits into a pattern that has accelerated sharply in recent years. Chinese companies struck more than 60 licensing agreements with U.S. and European pharmaceutical companies in 2025 alone, according to industry data, with at least eight more following in January 2026 — including a potential $6 billion oncology deal by AbbVie. The number of novel drugs submitted for clinical testing by Chinese developers rose from 688 in 2019 to 2,298 in 2023. Since 2021, China has registered nearly twice as many first-in-human trials for next-generation antibodies as the U.S. and Europe combined.

Analysts at data provider Pitchbook expect this trend to expand in 2026 into additional fields such as obesity programs, cell and gene therapies, and targeted drug delivery technologies — the Rona deal fits this pattern exactly. The usual rationale is that Western companies can acquire pre-vetted research results at a fraction of the cost of a full acquisition; that’s the analysts’ assessment, however, not a proven outcome. Nearly three-quarters of China licensing deals signed in 2025 also involved preclinical or Phase 1 assets — a very early, correspondingly high-risk stage of development at which most candidates industry-wide fail on the road to approval. Reliable success rates specifically for this wave of China deals aren’t yet available publicly, simply because most of the deals are too young to judge.

Roche is systematically building out its obesity portfolio

For Roche, the Rona deal isn’t an isolated move but another building block in a strategy that gained momentum with its $3.1 billion acquisition of Carmot Therapeutics in 2023. That acquisition already yielded several candidates now in clinical testing: an oral GLP-1 agonist (RG6652, Phase 1), a once-weekly GLP-1/GIP dual agonist (RG6640, Phase 2), and a daily GLP-1/GIP agonist being studied as an adjunct to insulin therapy in type 1 diabetes (RG6641, Phase 2). Added to that is an antibody against latent myostatin (RG6237), intended to counteract lean muscle loss during weight loss.

Just in early 2025, Roche also struck a deal worth up to $5.3 billion with Danish company Zealand Pharma for the amylin analog petrelintide ($1.4 billion upfront, another $250 million over two years, with the rest tied to milestones) — in a Phase 1b trial, the drug had shown nearly nine percent weight loss after 16 weeks. With Rona’s ALK7 candidate, Roche now adds a sixth mechanism to its pipeline, this one acting not on the brain but directly on fat tissue. The reasoning behind this diversification is hard to miss: Roche trails market leaders Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) in the high-margin obesity market and is trying to catch up through multiple parallel mechanisms and potential combination therapies — a path Novo Nordisk itself is also pursuing with its own amylin candidates.

Assessment

The Rona deal makes strategic sense on its own terms: a pharmaceutical company that needs to catch up in the industry’s most important growth market secures an additional, mechanistically distinct candidate at a fraction of what an acquisition would cost. At the same time, the risks shouldn’t be understated: the drug candidate demonstrably has no confirmed clinical data yet, the underlying delivery technology addresses one of the hardest unsolved problems in RNA therapeutics, and the deal is part of a China licensing wave whose long-term track record simply hasn’t been written yet, for lack of time. Whether the up-to-$1.16-billion deal eventually yields an approved drug will be decided not at the negotiating table, but in the clinical trials still ahead.

Sources

“Roche strikes obesity drug licensing deal worth up to $1.16 billion with Chinese Rona Therapeutics,” Reuters/KFGO, October 2026, https://kfgo.com/2026/10/13/roche-strikes-obesity-drug-licensing-deal-worth-up-to-1-16-billion-with-chinese-rona-therapeutics/
“Roche and Rona Sign $1.16B Deal for ALK7-Targeting RNAi Obesity Candidate,” Pharmacally, October 2026, https://pharmacally.com/roche-rona-therapeutics-alk7-rnai-obesity-deal/
“Roche licenses Rona Therapeutics obesity drug for up to $1.16B,” qz.com, October 2026, https://qz.com/roche-rona-therapeutics-obesity-alk7-rnai-deal-101426
“Roche strikes obesity drug licensing deal worth up to $1.16 billion with Chinese Rona Therapeutics,” Yahoo Finance, October 2026, https://finance.yahoo.com/healthcare/articles/roche-strikes-obesity-drug-licensing-081043221.html
“Roche strikes obesity drug licensing deal worth up to $1.16 billion with Chinese Rona Therapeutics,” Euronext/AP, October 2026, https://live.euronext.com/en/financial-news/roche-strikes-obesity-drug-licensing-deal-worth-116-billion-chinese-rona
“China biotech drug licensing trends: Pitchbook cell & gene therapy report,” BioPharma Dive, 2026, https://www.biopharmadive.com/news/china-biotech-drug-licensing-trends-pitchbook-cell-gene-therapy/810478/
“Major drugmakers turn to China for licensing deals,” Capital.com, 2026, https://capital.com/en-gb/news/major-drugmakers-turn-to-china-for-licensing-deals
Morgan Lewis: “The race for the next big weight-loss drug is on – and China wants in” (Wall Street Journal, cited), September 2026, https://www.morganlewis.com/news/2026/09/the-race-for-the-next-big-weight-loss-drug-is-on-and-china-wants-in
“The Great Delivery Wall: Why RNA Therapeutics Struggle to Leave the Liver,” Drug Discovery News, https://www.drugdiscoverynews.com/the-great-delivery-wall-why-rna-therapeutics-struggle-to-leave-the-liver-16834
“Moving RNA Therapeutics Beyond the Liver,” BioSpace, https://www.biospace.com/moving-rna-therapeutics-beyond-the-liver
“siRNA on the Precipice as Candidates Reach Beyond the Liver,” BioSpace, https://www.biospace.com/drug-development/sirna-on-the-precipice-as-candidates-reach-beyond-the-liver
“Roche builds in obesity with $5.3bn Zealand licensing deal,” pharmaphorum, March 2025, https://pharmaphorum.com/news/roche-builds-obesity-53bn-zealand-licensing-deal
“Inside the deal: Roche and Zealand Pharma’s $5.3 billion obesity drug gambit,” CNBC, https://www.nbclosangeles.com/news/business/money-report/inside-the-deal-roche-and-zealand-pharmas-5-3-billion-obesity-drug-gambit/3691856
“Roche moves obesity asset CT-388 into Phase III,” European Biotechnology, https://european-biotechnology.com/latest-news/roche-moves-obesity-asset-ct-388-into-phase-iii/
“Roche’s $2.5B obesity deal with Korea’s Hanmi,” Fierce Pharma, August 2026, https://www.fiercepharma.com/pharma/roche-25b-obesity-deal-akeso-ceo-defense-congressman-reflection-china

Adrian Kempf
Pharma Communications Writer, Graphic & Media Designer
Kirchzarten im Dreisamtal, Germany

Usage & Citation Permission

Full or partial reproduction of this text is permitted with source attribution. Please cite as: "Adrian Kempf, pharmavisuell.de"

This text may be forwarded, published, shared on social media, or posted publicly.

Editorial abridgment is permitted as long as the meaning and message of the text are not distorted.

This usage permission applies to the specialist articles published on pharmavisuell.de. Individually commissioned texts are subject to separately agreed usage rights.